0.00Open0.05Pre Close0 Volume3.02K Open Interest2.50Strike Price0.00Turnover315.55%IV56.41%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0351Delta0.0264Gamma112.40Leverage Ratio-0.0109Theta-0.0001Rho-3.95Eff Leverage0.0007Vega
Torrid Stock Discussion
Dow Jones· 3 mins ago
Torrid Reports Third Quarter Fiscal 2024 Results
5 minutes ago, 1:05 PM PST
Via BusinessWire
• Delivered Net Sales of $263.8 million
• Generated gross margin expansion of 285 basis points to 36.1%
• Net Loss of $1.2 million compared to Net Loss of $2.7 million last year
• Updated 2024 Net Sales and Adjusted EBITDA(1) Outlook
📊⚡️📊
$Yield10 Bioscience (YTEN.US)$ $Lytus Technologies Holdings (LYT.US)$ $Avalo Therapeutics (AVTX.US)$ $Gamida Cell (GMDA.US)$ $Torrid (CURV.US)$ $Qilian International (QLI.US)$
📊⚡️📊
📊⚡️📊
CURV soared 26% to trade at $6.15 shortly before 4:45 p.m. ET after the company reported a $0.04 loss per share – narrower than the $0.07 analysts had reportedly expected.
The company also recorded $293.5 million of quarterly revenues vs. the $276....
No comment yet